&lt;p&gt;Up-regulated long non-coding RNA DUXAP8 promotes cell growth through repressing Krüppel-like factor 2 expression in human hepatocellular carcinoma&lt;/p&gt;

Jiang, Hao; Shi, Xuefei; Ye, Guochao; Xu, Yongcan; Xu, Jiewei; Lü, Jun; Lu, Wei

doi:10.2147/ott.s214336

Cited by 42 publications

(33 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also proved that overexpression of DUXAP8 significantly promoted the proliferation, metastasis, and EMT of HCC cells; DUXAP8 knockdown repressed the malignant phenotypes of HCC cells. These data were consistent with previous report, 14 confirming DUXAP8 as an oncogenic lncRNA in HCC. miRNAs are at play in the progression of a variety of tumors.…”

Section: Discussionsupporting

confidence: 94%

“…Studies show that DUXAP8 exerts a regulatory role in esophageal squamous cell carcinoma, renal cell carcinoma, gastric cancer, and other tumors . A recent study reports that in HCC, DUXAP8 repressed tumor suppressor KLF2 transcription through interacting with EZH2 . However, the function and mechanism of DUXAP8 in HCC needs further exploration.…”

Section: Introductionmentioning

confidence: 99%

“…[11][12][13] A recent study reports that in HCC, DUXAP8 repressed tumor suppressor KLF2 transcription through interacting with EZH2. 14 However, the function and mechanism of DUXAP8 in HCC needs further exploration.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Long noncoding RNA DUXAP8 contributes to the progression of hepatocellular carcinoma via regulating miR‐422a/PDK2 axis

et al. 2020

View full text Add to dashboard Cite

Background Hepatocellular carcinoma (HCC) is one of the most deadly cancer worldwide. Multiple long noncoding RNAs (lncRNAs) are recently identified as crucial oncogenic factors or tumor suppressors. In this study, we explored the functon and mechanism of lncRNA double homeobox A pseudogene 8 (DUXAP8) in the progression of HCC. Methods Expression levels of DUXAP8 in HCC tissue samples were measured using qRT‐PCR. The association between pathological indexes and the expression of DUXAP8 was also analyzed. Human HCC cell lines SMMC‐7721 and QSG‐7701 were used in in vitro studies. CCK‐8 assay was used to assess the effect of DUXAP8 on HCC cell line proliferation. Scratch healing assay and Transwell assay were conducted to detect the effect of DUXAP8 on migration and invasion. Furthermore, dual‐luciferase reporter assay was used to confirm targeting relationship between miR‐422a and DUXAP8. Additionally, Western blot was used to detect the regulatory function of DUXAP8 on pyruvate dehydrogenase kinase 2 (PDK2). Results DUXAP8 expression HCC clinical samples was significantly increased and this was correlated with unfavorable pathological indexes. High expression of DUXAP8 was associated with shorter overall survival time of patients. Its overexpression remarkably facilitated the proliferation, metastasis, and epithelial‐mesenchymal transition of HCC cells. Accordingly, knockdown of it suppressed the malignant phenotypes of HCC cells. Overexpression of DUXAP8 significantly reduced the expression of miR‐422a by sponging it, but enhanced the expression of PDK2. Conclusions DUXAP8 was a sponge of tumor suppressor miR‐422a in HCC, enhanced the expression of PDK2 indirectly, and functioned as an oncogenic lncRNA.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long noncoding RNA DUXAP8 contributes to the progression of hepatocellular carcinoma via regulating miR‐422a/PDK2 axis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…With respect to lncRNAs included in prognostic signature, previous studies has revealed that ZFPM2-AS1 can promote proliferation and tumorigenesis of lung adenocarcinoma, renal cell cancer and gastric cancer [22][23][24]. Jiang H et al reported that dysregulated PCAT6 were significantly associated with HCC patients' poor outcomes [25]. Although there are no studies on the effect of AC145207.5, AL365203.2, AC009779.2, ZFPM2-AS1 and LINC00942 on the prognosis of HCC, KM analysis of these lncRNAs were significant difference in our present study.…”

Section: Discussionmentioning

confidence: 99%

Development of a prognostic signature based on six immune related lncRNAs for hepatocellular carcinoma.

Song¹,

Zhang²,

Li³

2020

Preprint

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumor in the world which prognosis is poor. Therefore, a precise biomarker is needed to guide treatment and improve prognosis. More and more studies have shown that lncRNAs and immune response are closely related to the prognosis of hepatocellular carcinoma. The aim of this study was to establish a prognostic signature based on immune related lncRNAs for HCC.Methods: Univariate cox regression analysis was performed to identify immune related lncRNAs, which had negative correlation with overall survival (OS) of 370 HCC patients from The Cancer Genome Atlas (TCGA). A prognostic signature based on OS related lncRNAs was identified by using multivariate cox regression analysis. Gene set enrichment analysis (GSEA) and a competing endogenous RNA (ceRNA) network were performed to clarify the potential mechanism of lncRNAs included in prognostic signature. Results: A prognostic signature based on OS related lncRNAs (AC145207.5, AL365203.2, AC009779.2, ZFPM2-AS1, PCAT6, LINC00942) showed moderately in prognosis prediction, and related with pathologic stage (Stage I&II VS Stage III&IV), distant metastasis status (M0 VS M1) and tumor stage (T1-2 VS T3-4). CeRNA network constructed 15 aixs among differentially expressed immune related genes, lncRNAs included in prognostic signature and differentially expressed miRNA. GSEA indicated that these lncRNAs were involved in cancer-related pathways. Conclusion: We constructed a prognostic signature based on immune related lncRNAs which can predict prognosis and guide therapies for HCC.

show abstract

“…MicroRNAs (miRNAs) are approximately 22-nucleotide-long noncoding RNA molecules that could regulate the target gene expression levels via binding to the 3'untranslated regions (3'UTR) of target gene at posttranscriptional level and promote degradation or inhibit translation 14 . The miR-635 is located in 17q and has been recently identi ed in colorectal cancer 15 .…”

Section: Introductionmentioning

confidence: 99%

Long Non-Coding RNA-DUXAP8 Regulates TOP2A in the Growth and Metastasis of Osteosarcoma via MicroRNA-635

Yang

Quo

Fan

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose: Osteosarcoma (OS) is a malignant tumor disease with high morbidity and mortality in children and adolescents. Evidence indicates that long non-coding RNAs (lncRNAs) may be important players in human cancer progression, including OS. In this study, we identified the role of lnc-DUXAP8 in the development of OS.Materials and Methods: Expression of lncRNA DUXAP8 was determined by real-time quantitative PCR and Western blotting in OS tissues. Cell proliferation was evaluated using CCK8 and colony formation assay; Transwell assay was conducted to measure cell invasion. Cell migration was evaluated using Wound Healing assay. The binding site between the lnc-DUXAP8 and miR-635 RNAs was evaluated using a luciferase reporter assay. Results: The expression of the lnc-DUXAP8 was significantly upregulated in OS samples and OS cell lines compared to normal tissue. High expression of lncRNA DUXAP8 was associated with shorter overall survival. Knockdown of lncRNA DUXAP8 inhibited proliferation and migration, and invasion in OS cells. More importantly, mechanism investigation revealed that lncRNA DUXAP8 was predominantly acted as a competing endogenous RNA (ceRNA) in OS by regulating miR-635/ TOP2A axis. Conclusion: LncRNA DUXAP8 is upregulated in OS, and LncRNA DUXAP8 knockdown plays a vital anti-tumor role in OS cell progression through a miR-635/ TOP2A axis. Our study suggests that LncRNA DUXAP8 may be a novel, promising biomarker for diagnosis and prognosis of OS.

show abstract

<p>Up-regulated long non-coding RNA DUXAP8 promotes cell growth through repressing Krüppel-like factor 2 expression in human hepatocellular carcinoma</p>

Cited by 42 publications

References 34 publications

Long noncoding RNA DUXAP8 contributes to the progression of hepatocellular carcinoma via regulating miR‐422a/PDK2 axis

Long noncoding RNA DUXAP8 contributes to the progression of hepatocellular carcinoma via regulating miR‐422a/PDK2 axis

Development of a prognostic signature based on six immune related lncRNAs for hepatocellular carcinoma.

Long Non-Coding RNA-DUXAP8 Regulates TOP2A in the Growth and Metastasis of Osteosarcoma via MicroRNA-635

Contact Info

Product

Resources

About